These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24284393)

  • 41. Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43.
    Tarutani A; Adachi T; Akatsu H; Hashizume Y; Hasegawa K; Saito Y; Robinson AC; Mann DMA; Yoshida M; Murayama S; Hasegawa M
    Acta Neuropathol; 2022 Jun; 143(6):613-640. PubMed ID: 35513543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prion-like properties of assembled TDP-43.
    Nonaka T; Hasegawa M
    Curr Opin Neurobiol; 2020 Apr; 61():23-28. PubMed ID: 31862626
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins.
    Corbett GT; Wang Z; Hong W; Colom-Cadena M; Rose J; Liao M; Asfaw A; Hall TC; Ding L; DeSousa A; Frosch MP; Collinge J; Harris DA; Perkinton MS; Spires-Jones TL; Young-Pearse TL; Billinton A; Walsh DM
    Acta Neuropathol; 2020 Mar; 139(3):503-526. PubMed ID: 31853635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Propagation of prions causing synucleinopathies in cultured cells.
    Woerman AL; Stöhr J; Aoyagi A; Rampersaud R; Krejciova Z; Watts JC; Ohyama T; Patel S; Widjaja K; Oehler A; Sanders DW; Diamond MI; Seeley WW; Middleton LT; Gentleman SM; Mordes DA; Südhof TC; Giles K; Prusiner SB
    Proc Natl Acad Sci U S A; 2015 Sep; 112(35):E4949-58. PubMed ID: 26286986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted proteolytic products of τ and α-synuclein in neurodegeneration.
    Xia Y; Lloyd GM; Giasson BI
    Essays Biochem; 2021 Dec; 65(7):905-912. PubMed ID: 34846537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Copper and iron ions accelerate the prion-like propagation of α-synuclein: A vicious cycle in Parkinson's disease.
    Li Y; Yang C; Wang S; Yang D; Zhang Y; Xu L; Ma L; Zheng J; Petersen RB; Zheng L; Chen H; Huang K
    Int J Biol Macromol; 2020 Nov; 163():562-573. PubMed ID: 32629061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The structural line between prion and "prion-like": Insights from prion protein and tau.
    Glynn C; Rodriguez JA; Hyman BT
    Curr Opin Neurobiol; 2024 Jun; 86():102857. PubMed ID: 38489865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein.
    Kumar H; Udgaonkar JB
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):922-932. PubMed ID: 30986567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experimental models of prion-like protein propagation.
    Hasegawa M
    Neuropathology; 2020 Oct; 40(5):460-466. PubMed ID: 32478452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrasensitive RT-QuIC Seed Amplification Assays for Disease-Associated Tau, α-Synuclein, and Prion Aggregates.
    Saijo E; Groveman BR; Kraus A; Metrick M; Orrù CD; Hughson AG; Caughey B
    Methods Mol Biol; 2019; 1873():19-37. PubMed ID: 30341601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders.
    Hasegawa M; Nonaka T; Masuda-Suzukake M
    Pharmacol Ther; 2017 Apr; 172():22-33. PubMed ID: 27916654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases.
    Hu C; Yan Y; Jin Y; Yang J; Xi Y; Zhong Z
    Neurosci Bull; 2024 Feb; 40(2):241-254. PubMed ID: 37755677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glycosaminoglycans, protein aggregation and neurodegeneration.
    Papy-Garcia D; Christophe M; Huynh MB; Fernando S; Ludmilla S; Sepulveda-Diaz JE; Raisman-Vozari R
    Curr Protein Pept Sci; 2011 May; 12(3):258-68. PubMed ID: 21348835
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physico-Pathologic Mechanisms Involved in Neurodegeneration: Misfolded Protein-Plasma Membrane Interactions.
    Shrivastava AN; Aperia A; Melki R; Triller A
    Neuron; 2017 Jul; 95(1):33-50. PubMed ID: 28683268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is tau ready for admission to the prion club?
    Hall GF; Patuto BA
    Prion; 2012 Jul; 6(3):223-33. PubMed ID: 22561167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases.
    Díaz-Nido J; Wandosell F; Avila J
    Peptides; 2002 Jul; 23(7):1323-32. PubMed ID: 12128089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Conformationally altered proteins cause neurodegenerative diseases].
    Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L
    Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. POSCAbilities: The Application of the Prion Organotypic Slice Culture Assay to Neurodegenerative Disease Research.
    Pineau H; Sim V
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32698402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
    Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
    J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.